Tarsus Pharmaceuticals, headquartered in Irvine, California, is dedicated to discovering and delivering breakthrough treatments for common and poorly treated diseases, starting with eye care. Their lead product candidate, TP-03, is a novel drug that targets the nervous system of Demodex mites to effectively treat Demodex blepharitis. With a pipeline of therapeutic candidates in various therapeutic categories, including dermatology, Tarsus aims to address high unmet needs and transform the lives of patients.